On 24 November 2025, the German Federal Ministry of Research, Technology and Space (BMFTR) published a funding guideline that supports transnational research projects within the framework of the European Partnership “One Health Antimicrobial Resistance” (EUP OHAMR). The aim is to develop innovative treatment options against antimicrobial resistance (AMR) and to improve treatment adherence in order to protect the health of humans, animals and the environment.

AMR is a growing global challenge, driven by the improper use of antibiotics and fungicides, leading to treatment failure and increased mortality. The EUP OHAMR, active since June 2025 and scheduled to run for ten years, connects 53 partners from 30 countries and focuses on research, capacity building and data management. The first joint call for research focuses on cost-effective treatment approaches and is supported by 36 funding organisations from 28 countries.

The funding aims to develop new combination therapies that increase the effectiveness of antimicrobials and slow down resistance, as well as to promote methods to improve therapy adherence. Projects should include at least three partners from different countries, including two EU member states or associated states, with a maximum network size of six groups. The involvement of end users such as patients or farmers is mandatory to ensure acceptance and relevance.

Financial support can be provided for expenditure on personnel, equipment, contract research and open access publications, with a maximum amount of 300,000 euros for a German project or 500,000 euros for two partners over up to three years. Approval is based on a three-stage procedure, starting with the submission of project outlines by 2 February 2026 and detailed applications by 17 June 2026. The funding is coordinated by a joint secretariat in France and is aimed at universities, research institutions, companies and civil society actors, with synergies through international cooperation being a prerequisite.

The directive will enter into force upon publication and will run until 30 June 2027, with a possible extension until 2033, depending on the validity of the underlying EU regulation. It aims to reduce the burden of disease caused by AMR and strengthen cooperation in the European Research Area.

Submission is made electronically via the Internet portal ( https://ptoutline.eu/app/OHAMR2026_OH-TREAT).

Original Publication:

Guideline for the Funding of Projects on Transnational Research Projects within the European Partnership One Health Antimicrobial Resistance on Combination Therapies and Therapy Adherence – Health Research BMFTR

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.